CureVac N.V.

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
2.44 ^USD	0.00%		-16.15%	-42.04%

Apr. 16	CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines	CI
Apr. 04	CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	MT

CUREVAC : Berenberg reaffirms its Buy rating

July 01, 2021 at 04:25 am EDT

In a research note published by Zhiqiang Shu, Berenberg advises its customers to buy the stock. The target price is unchanged and still at USD 123.

Latest news about CureVac N.V.

CureVac N.V. and the University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel Cancer Vaccines	Apr. 16	CI
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	Apr. 04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
CureVac, GSK's Seasonal Flu Shot Shows Efficacy in Phase 1/2 Study	Apr. 04	MT
CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK	Apr. 04	CI
CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK	Jan. 05	MT
GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates	Jan. 05	MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15	Dec. 27	DP
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	Dec. 22	MT
Global markets live: Fedex, Curevac, Shell, Fedex, Alphabet...	Dec. 20
Sector Update: Health Care Stocks Stronger Late Afternoon	Dec. 19	MT
Top Midday Decliners	Dec. 19	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Dec. 19	MT
Sector Update: Health Care	Dec. 19	MT
CureVac Patent Invalidated by German Court After BioNTech Nullity Action	Dec. 19	MT
German Patent Court Grants BioNTech's Nullity Action Against CureVac	Dec. 19	MT
CureVac Shares Hit All-Time Low on German Patent Court Ruling	Dec. 19	DJ
CureVac Patent Invalidated by German Court After BioNTech Nullity Action	Dec. 19	MT
German court quashes CureVac patent after challenge by BioNTech	Dec. 19	RE
German Patent Court Grants BioNTech's Nullity Action Against CureVac	Dec. 19	MT
CUREVAC : An untrimmed pipeline becomes costly	Nov. 29
CUREVAC : Unchanged cash drain	Nov. 28
European Patent Office declares Moderna mRNA patent invalid	Nov. 21	RE
CureVac N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : CureVac N.V., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people's lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Sector

Biotechnology & Medical Research

Calendar

2024-04-23 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

CUREVAC : An untrimmed pipeline becomes costly

November 29, 2023 at 02:56 am EST

More Strategies

Ratings for CureVac N.V.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.288 EUR

Average target price

11.42 EUR

Spread / Average Target

+399.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CUREVAC N.V.	-42.04%	546M
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B

Other Biotechnology & Medical Research

CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

CUREVAC : Berenberg reaffirms its Buy rating

Latest news about CureVac N.V.

Chart CureVac N.V.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for CureVac N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research